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Abstract: Background: Scleroderma (SSc) patients with active interstitial lung disease (ILD) experience a decline in lung 
function and increased mortality; cyclophosphamide (CYC) therapy may stabilize lung function at one and two years 
follow-up. Long-term lung function and survival outcomes of SSc patients with ILD following CYC treatment remain 
largely unknown. 
Methodology: We reviewed records of SSc patients with active ILD who had received at least six months of CYC 
treatment and had pulmonary function tests (PFTs) performed at least two years from the onset of treatment. 
Principal Findings: Thirty eight patients meeting eligibility criteria had a mean follow-up period from start of CYC to the 
last follow-up PFT of 5.1 years (range 2.3 -10.8 years). At a median of 4.1 years (range 9 months - 8.4 years), 12/38 
(32%) patients had a significant decline in % predicted Forced Vital Capacity from their baseline PFT. At a median of 3.9 
years (range 7 months - 8.4 years); 12/36 (33%) patients experienced a significant decline in their % predicted carbon 
monoxide diffusing capacity. Three patients died at a follow-up between 4.5-6 years and two received bilateral lung 
transplants because of severe restrictive lung disease. 
Conclusions: While the majority of SSc patients treated with CYC for active ILD experience long-term lung function 
stability and survive, greater than 1/3 of patients will experience either lung function decline, death, or require a lung 
transplant. This suggests that despite aggressive immune suppressing therapy, a subset of patients will have continued 
lung function decline, highlighting the need for ongoing monitoring and better therapeutic options. 
Keywords: Scleroderma, pulmonary fibrosis, cyclophosphamide. 
INTRODUCTION 
  Interstitial lung disease (ILD) is one of the leading causes 
of death among patients with systemic scleroderma (SSc) 
due to the fact that a significant subset of SSc patients will 
have progressive and severe restrictive lung disease [1, 2]. 
Two prospective, double-blind, randomized controlled trials 
have demonstrated that cyclophosphamide (CYC) stabilizes 
lung function in SSc patients with ILD [3-5]. While CYC’s 
effect on lung function is known up to a follow-up period of 
2 years, little is known about the sustainability of lung 
function response long term. Little is also understood about 
CYC’s effect on survival [3, 6]. This retrospective study was 
designed to determine long term lung function and survival 
in SSc patients with ILD who were treated with a course of 
CYC treatment and had more than 2 years of follow up data. 
MATERIAL AND METHODS 
Study Population 
  The Johns Hopkins Scleroderma Center database was 
screened for eligible SSc patients ever treated with CYC and 
seen in clinic from March 27, 1991 to April 30, 2006. Since 
medication data was routinely entered in the database after 
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2002, records of scleroderma patients who had a 
bronchoalveolar lavage (BAL) for evaluation of ILD prior to 
2002 were screened to identify patients treated with CYC, as 
it was standard practice in our center to perform BAL for 
evaluation for possible alveolitis [6-8]. 
  SSc patients with ILD treated with CYC were included if 
they met the following criteria: [1] had at least 6 months of 
CYC treatment [2], had been followed for at least 2 years 
from onset of CYC therapy, and [3] had a follow-up PFT 
more than 2 years from the PFT date at ILD diagnosis. The 
diagnosis of ILD was made clinically by the treating 
clinician; patients had to have at least one of the following: 
[1] pulmonary fibrosis with or without ground glass opacities 
on chest x-ray or computed tomography scan [2], an 
abnormal PFT (either percent predicted FVC or DLco 
<80%), or [3] an abnormal bronchoalveolar lavage. An 
abnormal BAL (alveolitis) was considered by the presence of 
 3% polymorphonuclear cells and/or  2% eosinophils. 
  Clinical and serologic variables recorded included: 
demographics, scleroderma subtype, presence of anti-
topoisomerase (anti-Scl-70) and anti-centromere antibodies 
(ACA), duration of CYC treatment, date of death or lung 
transplantation, last clinic visit date, and pulmonary function 
test (PFT) results. Patients were classified into either limited 
cutaneous scleroderma (lcSSc), if skin changes were limited 
to the distal limbs and/or face, or diffuse cutaneous 2   The Open Rheumatology Journal, 2011, Volume 5  Mittoo et al. 
scleroderma (dcSSc) if skin changes were on the proximal 
limbs and/or trunk [9, 10]. Pulmonary arterial hypertension 
was defined as either an estimated right ventricular systolic 
pressures of  40mmHg by Doppler echocardiography 
(ECHO) or a resting mean pulmonary arterial pressure (PAP) 
of > 25 mmHg with an associated pulmonary capillary 
wedge pressure < 15 mmHg by cardiac catheterization. Age 
at scleroderma onset was calculated from date of birth until 
the date of first non-Raynaud’s symptom. Disease duration 
was defined as duration from the first non-Raynaud’s 
symptom until ILD diagnosis. The date used for ILD 
diagnosis was the date of the PFT closest to initiation of 
CYC therapy. Follow-up period was defined as the date from 
CYC initiation until the date meeting one of the three 
defined endpoints (death, lung transplantation, or lung 
function decline). For those who did not have an event, the 
follow-up period was calculated from the date of CYC 
initiation until the latest available follow-up date (either last 
clinic visit or last PFT date, whichever occurred later). 
Ethics Statement 
  Clinical investigation of the scleroderma registry was 
with approval by Johns Hopkins institutional review board 
and was in accordance with the Declaration of Helsinki. 
Written informed consent was obtained from all participants 
involved in this study. 
CYC Treatment 
  The dose and duration of CYC treatment was determined 
by the individual treating physicians. It has been the typical 
practice of the authors to initiate 1mg/kg of body weight of 
daily oral CYC and to titrate to a goal of 2mg/kg of body 
weight provided no adverse events, toxicity, or signs of 
intolerance occurred. The typical recommended duration of 
CYC treatment increased over the study period from 6 to 18 
months, reflecting the authors (FW, RW, LH) change in 
clinical practice. Duration of CYC therapy was determined 
by record review. 
Pulmonary Function Tests (PFTs) 
  PFTs were routinely followed every 4-6 months; PFTs 
include spirometry, measurements of lung volumes, and a 
single-breath carbon monoxide diffusing capacity (DLco). 
Forced vital capacity (FVC), total lung capacity (TLC), and 
DLco were obtained from medical chart review and the 
center’s database. Although PFTs were not all performed at 
the Johns Hopkins center, all PFT data was standardized to 
same reference values [11-13]. PFT data used in this analysis 
were: 1. the PFT at the time of ILD diagnosis; 2. the PFT 
closest to the defined endpoints, occurring at least 6 months 
after of CYC treatment and 3. the latest PFT, for patients not 
meeting any endpoint. PFT results after lung transplantation 
were excluded from analysis. 
Endpoints 
  We defined 3 endpoints of interest: significant lung 
function decline, lung transplantation, and death. The 
endpoints had to occur at least 6 months after CYC 
initiation. To assess for possible survival bias, we compared 
the demographic features our study population to those with 
a positive BAL but with less than 2 years of follow up data. 
A clinically significant decline in lung function was defined 
as a decline of  10% predicted FVC or DLco on follow-up 
PFT compared to PFT values at ILD diagnosis; a clinically 
significant improvement was defined as an improvement of 
 10% predicted FVC or DLco on follow-up PFT compared 
to PFT [6]. Time until lung function decline, lung 
transplantation, or death was calculated from the date of 
CYC initiation until the date an endpoint was met. The last 
follow-up date for patients who did not meet a defined 
endpoint was either as the date of their last clinic visit or the 
date of last follow-up PFT, whichever date occurred later. 
Statistical Analysis 
  Continuous data are presented as a mean ± standard 
deviation (SD), or as median (range), for non-normally 
distributed data unless otherwise specified. Fisher’s exact 
test and unpaired t-test were used to analyze the two groups 
with respect to age of onset, gender, race and mortality. 
Paired t-test was used to analyze change in percent predicted 
FVC and DLco from baseline and follow-up. Kaplan Meier 
graphs were generated for individual and combined 
endpoints. 
RESULTS 
  Ninety three patients seen at the Johns Hopkins 
Scleroderma Center from March 1991 to April 2006 were 
identified as having received CYC for ILD. Among those 
screened, 38 patients met our pre-review criteria. Reasons 
for exclusion included: a treatment period of less than 6 
months (24 patients), a follow-up period of less than 2 years 
(20 patients), and incomplete data (11 patients). Of the 20 
patients with less than 2 years of follow-up, 6 had died 
compared with 5 out of 38 patients who died or had a lung 
transplant (p=0.16). No significant differences were seen by 
age at SSc onset, gender, or race between the study 
population and the 20 patients with less than 2 years of 
follow-up. The six deaths that occurred in this comparison 
group included 2 due to severe ILD complicated by severe 
cardiomyopathy, 1 due to a failed lung transplant for severe 
ILD, and 1 from a combination of severe ILD and PAH. One 
patient died of a suicide and one died of likely pulmonary 
embolus. 
  The baseline characteristics of the 38 patients are 
presented in Table 1. All patients met ACR criteria for the 
diagnosis of scleroderma [9]. The majority were women (26 
patients, 68%) and Caucasians (28 patients, 74%) with an 
age of onset of 44.3 ± 11.4 years. Twenty-two dcSSc and 16 
lcSSc were followed for an average of 5.1 years (range 2.3 -
10.8 years) from start of CYC until end of study follow-up 
period. Eighteen out of 36 patients (50%) screened had a 
positive anti-topoisomerase antibody and only one out of 35 
patients screened was anit-centromere positive. The median 
duration of CYC treatment was 1.4 years (range 6 months-
6.7 years). Twelve patients had up to a year of CYC, 17 had 
1-2 years, 9 had >2 years of treatment. Among the 9 patients 
treated for >2 years; 1 had 26 months, 2 had 30 months, 1 
had 32 months, 1 had 35 months, 1 had 38 months, 2 had 41 
months, and 1 had 80 months of CYC. Thirty-seven out of 
38 patients had abnormal baseline PFTs; one patient with a 
normal baseline PFT had an abnormal BAL. Long Term Effects of Cyclophosphamide Treatment on Lung Function  The Open Rheumatology Journal, 2011, Volume 5   3 
PFT Endpoint 
Forced Vital Capacity 
  The mean % predicted FVC at follow-up was 62.3 ± 
19.6%, which was a mean decline of 1.0% (95% CI of -6.2 
to 4.2%) from baseline. There was no significant difference 
between the % predicted FVC at baseline and at follow-up 
(p=NS). Nine (24%) patients had a significant improvement, 
12 (31%) had a significant decline, and 17 (45%) had stable 
lung function at follow-up. 
  At a median of 4.1 years from start of CYC therapy, 
sixty-eight percent of patients had a stable FVC while 12 out 
of 38 patients (32%) had a significant decline (Fig. 1). 
Among the 12 patients with a significant decline in FVC, 10 
were treated for greater than 1 year with CYC and 4 had 
greater than 2 years of CYC treatment. 
Single Breath Carbon Monoxide Diffusing Capacity 
  Values for DLco were not available on follow-up PFT for 
2 patients. The % predicted DLco at follow-up was 54.8 ± 
26.4%, which declined 1.5 % from baseline (95% CI of [-
9.8% to 6.7%], p=NS). Sixty-seven percent (24/36) of the 
study population had stable DLco. Thirty three percent of 
patients (12/36) experienced a significant DLco decline in a 
median of 3.9 years (range 7 months - 8.4 years) (Fig. 2). 
Five out of these 12 patients had a diagnosis of pulmonary 
hypertension by ECHO and 2 patients had their diagnosis 
subsequently confirmed by cardiac catheterization; 9 out of 
12 patients had greater than 1 year of CYC treatment and 4 
had greater than 2 years of treatment. 
 
Long Term Survival and Lung Transplantation 
  Three subjects died during the study period. Two patients 
died as a result of pulmonary arterial hypertension. Both 
patients experienced a significant drop in DLco at a follow 
up period of 7.5 months, with a DLco drop of 37.4%, and 
26.4 months, with a DLco drop of 17.7%; one patient also 
had a significant drop in FVC at 3.5 years of 13.9 %. One 
patient died of an unknown cause at a follow-up of greater 
than 5 years and had experienced a significant drop in DLco 
7 months into treatment; the % predicted FVC and DLco on 
the last available PFT was 110.5% and 78% respectively. 
This patient had no evidence of PAH at last ECHO. 
  Two patients received bilateral lung transplants for 
severe restrictive lung disease. One patient had a severe 
restrictive lung disease 32 months from initiation of CYC; 
the % predicted FVC at time of transplant was 44.3% 
compared with their baseline of 43%. There was no DLco 
data available for this patient at time of transplantation. 
Another patient, transplanted 48 months after initiation of 
CYC, had a significant decline only in FVC (drop from 
71.1% to 27.1% at 36 months) with a stable DLco (49.5% at 
baseline and 44.7% at follow up). 
Combined Lung Function, Survival, and Lung 
Transplantation Endpoints 
  Seventeen out of 38 patients (45%) experienced lung 
function decline, death, or a lung transplant at a median of 
2.95 years (range 6.7 months – 8.4 years) from CYC 
initiation (Fig. 3). While lung function decline occurred 
more frequently by 2 years, lung transplantation or death 
occurred with greater frequency after 2 years. 
Table 1.  Baseline Clinical Characteristics of Study Population (N=38) 
 
 Characteristics  Results 
Age of SSc onset mean ± SD (range), in years  44.3 ± 11.4 (21-74) 
Disease duration at ILD diagnosis mean ± SD (range), in years  4.6 ± 4.6 (0-23) 
Gender 
 Female: Male, n (%)  26 (68): 12 (32) 
Race  
 Caucasian, n (%) 28  (74) 
 African American, n (%) 7(18) 
 Other, n (%)   3 (8) 
Subtype  
 lcSSc: dcSSc, n (%)  16 (42): 22 (58) 
Autoantibody Status  
 positive ACA, n  1   
 positive anti-TPO, n  18 
Baseline % predicted FVC, mean ± SD (range)  63.3 ± 12.4 (39.4-95.5) 
Baseline % predicted DLco, mean ± SD (range)  52.6 ± 16.4 (26.2-102.1) 
Follow-up period mean ± SD (range), in years   5.1 ± 2.1 (2.3-10.8) 
Duration of CYC therapy mean ± SD (range), in months  20.3 ± 13.6 (6 months-6.7 years) 
Legend: ACA- anti-centromere antibody: 3 missing ; Anti-TPO-anti-topoisomerase antibody: 2 missing; SSc- systemicscleroderma; CYC-cyclophosphamide; FVC- forced vital 
capacity; DLco-single-breath carbon monoxide diffusing capacity; lcSSc- limited cutaneous scleroderma; dcSSc-diffuse cutaneous scleroderma. 4   The Open Rheumatology Journal, 2011, Volume 5  Mittoo et al. 
DISCUSSION 
  We found that 55 and 75% of CYC-treated SSc patients 
with active ILD have a stable FVC and DLco at a median 
follow-up of 4.5 years, respectively. We also found that the 
6-year survival rate post-CYC treatment is 60%, however, 
around 40% of SSc patients with ILD have continued lung 
function decline despite treatment. 
 
Fig. (1). Kaplan-Meier Graph for % Predicted FVC decline. Numbers are persons at risk at each interval. 
 
Fig. (2). Kaplan-Meier Graph for % Predicted DLco decline. Numbers are persons at risk at each interval. 
 
Fig. (3). Kaplan-Meier Graph of combined endpoint. Numbers are persons at risk at each interval. 
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  The median survival of SSc-ILD, defined as fibrosis on a 
chest X ray and a % predicted FVC<55%, is estimated at 3 
years from the onset of organ involvement. CYC treatment is 
thought to be effective at limiting lung function decline in 
SSc patients with active ILD. The first randomized, 
controlled trial of SSc patients with active ILD showed a 
significant, although modest improvement in lung function 
after CYC treatment compared with placebo at one year, but 
not at 2 years of follow-up [3, 4]. Approximately 7% of 
CYC-treated patients had a clinically significant decline in 
lung function, defined as 10% change in percent predicted 
FVC from baseline to 1 year; the percentage of CYC-treated 
patients with a clinically significant decline in lung function 
at 2 years was not reported. We found that 3% and 14% of 
treated patients had a 10% percent predicted FVC decline at 
1 and 2 years follow-up, respectively; unfortunately, there 
was no placebo group to provide a comparison. However, 
data from the placebo arm of a randomized clinical trial of 
SSc-ILD revealed an average rate of decline in % predicted 
FVC of –2.01 per unit score for
 fibrosis [3]. 
  There are few studies of CYC-treated SSc patients with 
ILD having lung function follow-up of greater than 2 years 
[14-16]. A retrospective study by White et al. of SSc patients 
with ILD seen at our Center from 1991-1998 showed that 
CYC-treated patients followed for a median of 16 months 
had stabilization in lung function, as measured by FVC and 
DLco [6]. Another study of 13 SSc ILD patients, who were 
treated with intravenous (IV) monthly pulse CYC and 
methylprednisolone, showed that 60% had stabilization in % 
predicted FVC or DLco at 48 months [15]. Other studies of 
13 and 14 SSc ILD patients also yielded similar results at 12 
and 26 months follow-up, respectively [14, 16]. We 
observed a large group of SSc patients who had serial PFTs 
with a mean follow-up of 4 years and found around 60% of 
patients, a similar proportion to these other studies, had long 
term lung function stabilization. Our study also extends the 
work by White et al. and includes a broader, more clinically 
applicable definition of ILD as opposed to defining ILD only 
as patients who have had an abnormal BAL or lung biopsy 
result. Our study population also included patients with 
milder restrictive lung disease who were treated with a 
longer period of CYC compared with the population 
evaluated by White et al. 
  Few studies have examined the effect of CYC on 
survival. In the Scleroderma Lung Study, the CYC-treated 
patients had a significant improvement in combined endpoint 
of death and FVC at 12 months compared with placebo and 
57 out of 73 CYC-treated patients (78%) were alive at 2 
years [3, 4]. In a retrospective study of SSc patients by 
White  et al., 39 CYC-treated patients identified as having 
ILD by a BAL had a median survival rate of 89%; 10 
patients survived for up to 4.8 years [6]. However, these 
patients had variable severity of ILD and pulmonary 
hypertension. 
  We report in this study our experience from a large 
number of well-characterized CYC-treated patients followed 
longer than two years with respect to lung function and 
mortality. Limitations in our study include its retrospective 
design and analysis of a selected group of SSc patients who 
were treated with CYC and who survived for two or more 
years. Thus, while this study population does not reflect 
those who have early mortality, it does give insight into the 
projected long-term course of patients who do complete a 
course of CYC treatment and who survive for longer than 
two years. We could not find variables that predicted adverse 
outcomes, but the study population was not large enough to 
reliably evaluate subgroups. Although there seemed to be no 
significant differences in mortality between our study 
population compared to the group of patients with < 2 years 
of follow-up, there were more deaths attributable to ILD in 
this latter group, suggesting that ILD was less severe in our 
study population. Moreover, 2 out of the 3 deaths that 
occurred in our study population were due to PAH. This may 
indicate that patients who survive beyond 2 years are less 
likely to die from ILD. 
  Our findings imply that CYC limits the progression of 
lung disease in many, but not all SSc patients. Roughly one 
third of patients experience continued decline despite 
“standard of care treatment”, highlighting the need for 
continued lung function monitoring and alternative 
treatments. It will be important to determine if other anti-
fibrotic, anti-inflammatory, or immunosuppressive agents 
will be superior or safer than CYC and if maintenance 
therapy is required after inducing a clinical response with 
CYC therapy. This study also did not address the strategy of 
maintenance immunosuppressive therapy after a course of 
CYC or re-treatment with another agent in the setting of 
evidence of progressive disease despite CYC therapy. We 
found that SSc patients treated with CYC for periods greater 
than one year did not have significantly different lung 
function outcomes compared to those treated less than 12 
months, albeit the size of our study population was small. 
We cannot exclude that a proportion of patients who 
experienced a decline in DLco had unrecognized pulmonary 
arterial hypertension. 
  In conclusion, we report our experience with CYC-
treated SSc patients with ILD and find that most patients 
have a good long-term prognosis, both in terms of lung 
function and survival. However, there remain a proportion of 
patients who will have lung function decline despite 
treatment with CYC. 
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